Quest, IBM bring artificial intelligence to genomic tumor data

It’s difficult for physicians to routinely incorporate genomic tumor data into patient treatment decisions, not only because of the complexity and difficulties of the data itself, but also because so few treatments lend themselves to treating specific genetic tumor types. IBM Watson Health ($IBM) and Quest Diagnostics ($DGX) aim to make at least one aspect of that equation much easier by offering broad-based access to cognitive computing analysis of genomic tumor sequencing. The partners have launched the service, known as IBM Watson Genomics from Quest Diagnostics, and rolled it out to all of Quest’s customers, which includes half of U.S. physicians and hospitals including community oncologists who provide an estimated 70% of all cancer care in the country. “Through this collaboration with the cancer community’s leading clinical and pathology experts, thousands…


Link to Full Article: Quest, IBM bring artificial intelligence to genomic tumor data